Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life threatening microangiopathic disorder. Before the introduction of plasma exchange therapy, mortality was extremely high (1) . It is related to hemolytic uremic syndrome (HUS) but can be differentiated from HUS by the more general involvement of many organs compared to the more localized manifestation of HUS in the kidneys, although some overlap of symptoms may occur. It has first been described by Eli Moschcowitz in 1924 (2) , who presented the case of a previously healthy 16 year old girl with fever, pallor, petechiae, acute renal failure and paralysis who died one week after falling ill. Post-mortem histology revealed hyaline platelet thrombi in almost every organ. Reports on similar cases with a congenital onset and/or familial manifestation, compared to first manifestation in adolescence and adulthood indicated the presence of an inherited and an acquired form of the disease, respectively (3) (4) (5) (6) (7) (8) (9) . Although the beneficial effect of plasma infusions suggested a deficiency of an essential plasma factor in the patients (4, 6) , the nature of the disease causing factor remained obscure until Moake et al. detected unusually large VWF multimers (ULVWFM) in the plasma of four patients during their remission from TTP (10) . Relapses of TTP were accompanied by a decrease of these ULVWFM, suggesting consumption by binding to aggregating platelets. The authors proposed a defect in the processing of the very large VWF multimers after synthesis and secretion by endothelial cells, making the patient susceptible to repeated relapses. This processing defect was identified as deficiency of a VWF specific metalloprotease (11, 12) , that cleaves VWF at a defined position in the VWF A2 domain between Tyr 1605 and Met 1606 (13) . A partial amino acid sequence was determined independently by three groups in 2001 (14 -16) .
Based on this information VWF-CP was identified as a member of the ADAMTS family of metalloproteases. The cDNA sequence was determined (17) and a database search revealed the structure of the gene on chromosome 9q34. Parallel to the biochemical approach, the For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From responsible gene locus was mapped to 9q34 by linkage analysis and identification of specific mutations in ADAMTS13 (18) . Review of the literature reveals very similar courses of congenital TTP in different patients over the years. The reported cases display the full spectrum of symptoms, though not always concurrent at the same time.
Occasionally, thrombocytopenia can be the only symptom, but the full-blown clinical picture seems to manifest in later childhood or after puberty and to correlate with certain episodes of infection, stress, alcohol consumption or with pregnancy (3) (4) (5) (6) (7) (8) (9) . Therefore, especially in early childhood, oligosymptomatic forms may be more frequent, complicating the differential diagnosis. In order to assess the clinical picture of VWF-CP deficiency in cases of chronic relapsing thrombocytopenia and hemolytic anemia, we determined VWF-CP activity in children with the presumed diagnosis of ITP, TTP, HUS and Evans syndrome and carried out mutation analysis of the ADAMTS13 gene to establish the molecular background and the spectrum of mutations in our population.
Patients and Methods
We investigated 83 children with hemolytic and/or thrombocytopenic episodes with or without additional neurological symptoms or renal failure. The presumed diagnosis was chronic immune thrombocytopenia (ITP, n=50), thrombotic thrombocytopenic purpura (TTP, n=8), hemolytic uremic syndrome (HUS, n=24) and Evans syndrome (n=1). The clinical course of our patients with TTP was rather variable, ranging from isolated thrombocytopenia, at least at some occasions, to the full pentad of symptoms (2) and to death of disease (s. Table 3 ). Among the 24 patients with HUS, there were seven with atypical forms: in two children HUS was non enteropathic, and one of these two suffered from a relapse after renal transplantation. Two other patients had a relapsing course, and one of them had an affected sibling. Three additional patients with enteropathic symptoms also had affected siblings.
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Assay of VWF-cleaving protease by the collagen binding method
The activity of the VWF-CP is determined essentially as described (19) . The only modification is the use of recombinant VWF (rVWF) as substrate (20) . The rVWF preparation is a fully multimerized molecule and, due to the lack of VWF-CP activity in the cell culture medium in an uncleaved state, displaying no triplet pattern. To avoid proteolysis by other proteases it is treated with Pefabloc SC (Roche, Mannheim, Germany) and EDTA in final concentrations of 2 and 15 mM, respectively. Thereafter it is dialyzed against 4 % polyethylene glycol 20,000 (Merck, Darmstadt, Germany) and 5 mM Tris, pH 8.0 (20) . This preparation with a rVWF concentration of 1.0-1.6 U/ml is stored in aliquots at -80°C. After thawing it was equilibrated with 1.5 M Urea and used as the substrate for the VWF-CP. Plasma of a patient with severe VWD type 3 and normal VWF-CP served as a normal control. Digestion of rVWF (final concentrations between 0.6 to 0.9 U/ml) by VWF-CP and the collagen binding assay of the digested samples is performed as described (19) . VWF multimer analysis was carried out in SDS agarose gels combined with immunoblotting and luminescent visualization (21) (Table 1) . Sequencing was carried out on both strands. Mutations were confirmed by an independent method like restriction enzyme digest. If not otherwise stated, in the case of using kits, we followed the instructions of the provider.
Mutation screening of the VWF-A2 domain
Besides VWF-CP deficiency itself, TTP could theoretically also be caused by an intrinsic resistance of VWF to proteolysis. However, naturally occurring respective VWF mutations have not been reported to date. We analyzed the VWF A2 domain of all patients with HUS and of two patients with TTP for whom no VWF-CP data were available, for possible VWF cleavage site mutations by PCR amplification of VWF exon 28 and direct sequencing as reported previously (20) .
Mutation screening of ADAMTS13
All coding exons and flanking intron sequences of the ADAMTS13 gene were amplified by PCR using either published primers (18) or primers chosen from the published sequence (Genbank accession numbers: AL158826, AC002325; s. Table 1 ). All PCR products were sequenced directly using an ABI 310 or an ABI 377 automatic sequencer. In the case of a dinucleotide deletion and a single nucleotide insertion, respectively, PCR products were also sequenced after cloning. Screening for identified mutations among relatives of patients and 50 normal controls (100 alleles) was done either directly by PAGE of PCR products in the case of a dinucleotide deletion, or by PAGE after restriction enzyme digest (Table 2) .
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VWF cleaving protease
Data obtained from the VWF-CP assay are illustrated in Fig. 1 . Among the 24 patients with HUS, none had VWF-CP activities below 62% (range 62-185%, median 103%)
Among the patients with the presumed diagnosis of ITP, two had VWF-CP deficiency with activities < 2% of normal. However, since both also had mild Coomb's negative hemolytic anemia, the former diagnosis was changed to possible TTP. All other ITP patients had values 33% (range 33-175%, median 59%) All tested patients with the diagnosis of TTP had VWF-CP values 5% and, except one, even below the limit of detection at 2% at least at one or more occasions. (Fig. 1 ).
For Table 3 .
The VWF collagen binding assay is relatively easy to perform and is faster than VWF multimer analysis for determination of VWF-CP activity. However, the action of VWF-CP on VWF is better visualized by the specific VWF cleavage pattern. VWF-CP causes loss of large VWF multimers, and generates the typical triplet structure of plasma VWF oligomers. (Actually, a quintuplet structure with inner subbands is present that can be visualized by high resolution gels (22) ). This triplet structure is absent in native TTP plasma, in untreated recombinant VWF, and, accordingly, after incubation of rVWF with VWF-CP deficient plasma. The appearance of pronounced triplets after mixing either VWF-CP deficient plasma or rVWF with plasma from a patient deficient in VWF but with normal VWF-CP, illustrates the specific action of the protease on VWF (Fig. 2) . -12 -Five different molecular defects were truncating mutations, suggesting a causative nature, three were candidate missense mutations. Only one patient was homozygous, whereas the remaining six patients were compound heterozygotes for two mutations each. One mutation (4143insA) is particularly frequent and was found in four unrelated German patients. One missense mutation (1058C>T; P353L) and one nonsense mutation, (2728C>T; R910X), respectively, were identified in two patients each, whereas six mutations were confined to single families.
695T>A in a Turkish patient (05 I-1) is located in exon 7 and predicts the exchange of leucine 232 to glutamine (L232Q) in the metalloproteinase domain. Homozygosity for the mutation and an intragenic haplotype suggests consanguinity. The clinical course of this patient must be considered as severe due to renal infarction and to neurological sequelae following stroke, and the need for continuous replacement therapy by FFP.
788C>G is located in exon 7 and predicts the exchange of serine 263 to cysteine (S263C) in the metalloproteinase domain. It is found in patient 01 II-1 in combination with 4143insA, a truncating single base insertion in exon 29. He has inherited S263C from his father and 4143insA from his mother (Table 3) . To date the only symptoms were mild hemolysis and thrombocytopenia.
1058C>T is located in exon 9 and predicts the exchange of proline 353 to leucine (P353L) in the disintegrin domain. This mutation was found in two unrelated patients, both living in the same region in Northern Germany at the border to Denmark. Patient 03 II-1 was also compound heterozygous for the nonsense mutation 2728C>T (R910X). She was misdiagnosed with Evans syndrome and died from her disease at the age of three. The correct diagnosis was made from archived DNA, eight years post mortem. Patient 10 II-1, with a clinically benign course and VWF-CP residual activity between < 2% and 6 % of normal, had 4143insA as second mutation which he inherited from his father (Table 3) .
org From
Schneppenheim et al.
-13 -1169G>A in exon 10 (W390X) and an additional truncating mutation, a dinucleotide deletion, in exon 20 (2549-2550delAT) were identified in Patient 08 II-1. W390X was inherited from the father and 2549-2550delAT from the patient's mother (Table 3) . The patient had a severe clinical course with stroke episodes and she is mentally retarded. She is on continuous replacement therapy with FFP. VWF-CP values were not available.
3100A>T in exon 24 (R1034X) and 4143insA were detected in patient 04 II-1. She had severe clinical symptoms including neurologic and renal involvement. Her VWF-CP was < 2% of normal. She is on continuous replacement therapy with a virus inactivated commercial plasma preparation. 4143insA was inherited from the father, R1034X from the patient's mother ( Table 3 ). The patient's unaffected brother is heterozygous for R1034X.
In all investigated cases, asymptomatic family members who were heterozygous for one of the mutations, displayed VWF-CP values corresponding to the heterozygous state and were clinically not affected (Table 3) .
By screening of 100 normal alleles none of the mutations was detected in the controls.
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Discussion
Although reliable incidence data are not available, TTP is a rare disease in childhood. Our study however points to the possibility of underdiagnosis in the past. In our cohort, three patients were misdiagnosed as having Evans syndrome and ITP, respectively. It is of interest that the child with TTP reported by Schulman also had a previous diagnosis of ITP (4) . These cases illustrate that oligosymptomatic forms may occur with the possibility of misdiagnosis. However, most probably even these patients may eventually suffer from severe TTP episodes when precipitating factors trigger the pathophysiological cascade that has recently been elucidated. To identify such patients and to differentiate between the acquired and the hereditary form is of crucial importance for immediate care and adequate therapy in acute phases of the disease. Today this can be reliably done by assessing the VWF-CP activity, by screening for VWF-CP inhibitors and, since recently, by performing mutation analysis of the ADAMTS13 gene.
All mutations reported to date were confined to single families and most of them were missense mutations (18) . None of the ADAMTS13 mutations that we identified in our patients has been described before. In contrast to the first report (18) we found a higher rate of truncating mutations. One mutation (4143insA) is particularly prevalent in our population and was found in four compound heterozygous patients. Only three mutations were missense mutations that can only be regarded as candidates, since to date expression studies are pending. However, one of them (L232Q) was found in homozygous form, and another one (P353L) was found in two unrelated patients. Furthermore, none of the eight different mutations was detected among 100 alleles of normal controls.
A correlation between phenotype and genotype of congenital TTP is hard to establish. The patients' history is suggestive that precipitating factors like infections have more impact on the severity of TTP episodes than the genotype. Due to the complex mutation spectrum in However, in conclusion, it seems that severe VWF-CP deficiency with values below 5% of normal is rather indicative of TTP than of HUS.
Although theoretically possible, we could not detect mutations of VWF that would provide resistance against the proteolytic action of VWF-CP in the patients with HUS. VWF-CP resistance does not seem to contribute significantly to the pathomechanism of HUS.
Two different forms of childhood TTP were observed among our patients. Four patients had the acquired form, most probably caused by autoantibodies against the protease. The inconsistent detection of VWF-CP inhibitors even during longer periods of severe VWF-CP deficiency in these patients complicates the correct classification which is crucial for the adequate treatment. Possibly, the Bethesda method for the identification of VWF-CP antibodies is not sensitive enough to detect low titer -though effective -inhibitors.
Patients with an inhibitor need a more aggressive therapy, including plasma exchange and immunosuppression, whereas patients with the hereditary form can be treated by VWF-CP replacement therapy alone. Due to the long half-life of VWF-CP of 2 -3 days (26) and the clinical efficacy even at low VWF-CP values, plasma infusion every 2 weeks seems sufficient. This is also confirmed by the clinical response to such prophylaxis in some of our patients (27 and unpublished observations).
In all of our patients without an inhibitor we identified ADAMTS13 mutations on both alleles which is in accordance with the autosomal recessive inheritance of inborn VWF-CP deficiency, whereas no mutation was found in patients with a significant inhibitor detected For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From -17 -at least at one time point. Although exact data are lacking, it seems that childhood TTP is more often caused by hereditary VWF-CP deficiency which would agree with the lower incidence of autoimmune disease in children compared to adults. Given the impact of the correct classification of TTP with respect to therapy and genetic counseling we propose molecular genetic testing in children with severe VWF-CP deficiency.
